Chatchai Muanprasat

Prof. Dr. Chatchai Muanprasat


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
CMChatchai Muanprasat
Chatchai Muanprasat
VCVaranuj Chatsudthipong
Varanuj Chatsudthipong

16 December 2020 in Molecules
Verified
Journal Article
Open access
PDF file
SSSaravut Satitsri
Saravut Satitsri
CMChatchai Muanprasat
Chatchai Muanprasat
Chitin is a long-chain polymer of N-acetyl-glucosamine, which is regularly found in the exoskeleton of arthropods including insects, shellfish and the cell wall of fungi. It has been known that chitin can be used for biological and biomedical applications, especially as a biomaterial for tissue repairing, encapsulating drug for drug delivery. However, chitin has been postulated as an inducer of proinflammatory cytokines and certain diseases including asthma. Likewise, chitosan, a long-chain polymer of N-acetyl-glucosamine and d-glucosamine derived from chitin deacetylation, and chitosan oligosaccharide, a short chain polymer, have been known for their potential therapeutic effects, including anti-inflammatory, antioxidant, antidiarrheal, and anti-Alzheimer effects. This review summarizes potential utilization and limitation of chitin, chitosan and chitosan oligosaccharide in a variety of diseases. Furthermore, future direction of research and development of chitin, chitosan, and chitosan oligosaccharide for biomedical applications is discussed.

1 August 2015 in Biochemical Pharmacology
Verified
Journal Article
Closed access
CMChatchai Muanprasat
Chatchai Muanprasat
PWPreedajit Wongkrasant
Preedajit Wongkrasant
SSSaravut Satitsri
Saravut Satitsri
AMAekkacha Moonwiriyakit
Aekkacha Moonwiriyakit
PPPawin Pongkorpsakol
Pawin Pongkorpsakol
VCVaranuj Chatsudthipong
Varanuj Chatsudthipong

1 July 2016 in Carbohydrate Polymers
Verified
Journal Article
Closed access
TMTharinee Mattaveewong
Tharinee Mattaveewong
PWPreedajit Wongkrasant
Preedajit Wongkrasant
SCSumalee Chanchai
Sumalee Chanchai
RPRath Pichyangkura
Rath Pichyangkura
VCVaranuj Chatsudthipong
Varanuj Chatsudthipong
CMChatchai Muanprasat
Chatchai Muanprasat

1 September 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
PWPreedajit Wongkrasant
Preedajit Wongkrasant
PPPawin Pongkorpsakol
Pawin Pongkorpsakol
JAJutharat Ariyadamrongkwan
Jutharat Ariyadamrongkwan
RMRoojanaat Meesomboon
Roojanaat Meesomboon
SSSaravut Satitsri
Saravut Satitsri
CMChatchai Muanprasat
Chatchai Muanprasat
Tight junctions play an important role in maintaining barrier integrity of intestinal epithelia. Activation of AMP-activated protein kinase (AMPK) promotes tight junction assembly in intestinal epithelial cells (IEC). Fructo-oligosaccharides (FOS), well-known prebiotics, have previously been shown to alleviate inflammation-associated intestinal epithelial disruption although the mechanisms were unclear. This study aimed to investigate any effect of FOS on AMPK activity and tight junction assembly under non-inflammatory and inflammatory conditions using T84 cells as an IEC model. As analyzed by western blot, FOS induced AMPK activation through a calcium sensing receptor (CaSR)-phospholipase C (PLC)- Ca2+/calmodulin-dependent protein kinase kinase-β (CaMKKβ) pathway. Calcium switch assays and immunofluorescence staining of zonula occludens-1 (ZO-1) revealed that FOS induced tight junction assembly via an CaMKKβ-AMPK-dependent mechanism in IEC. Interestingly, FOS reversed the suppressive effect of lipopolysaccharide (LPS) on AMPK activity and tight junction assembly via a CaMKKβ pathway. Taken together, these findings uncover a prebiotic-independent effect of FOS in promoting intestinal epithelial tight junction assembly through AMPK activation, which may have implications for the treatment of diseases whose pathogenesis involves impaired intestinal barrier function.

15 June 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NPNutthapoom Pathomthongtaweechai
Nutthapoom Pathomthongtaweechai
CMChatchai Muanprasat
Chatchai Muanprasat
The small intestine provides the major site for the absorption of numerous orally administered drugs. However, before reaching to the systemic circulation to exert beneficial pharmacological activities, the oral drug delivery is hindered by poor absorption/metabolic instability of the drugs in gastrointestinal (GI) tract and the presence of the mucus layer overlying intestinal epithelium. Therefore, a polymeric drug delivery system has emerged as a robust approach to enhance oral drug bioavailability and intestinal drug absorption. Chitosan, a cationic polymer derived from chitin, and its derivatives have received remarkable attention to serve as a promising drug carrier, chiefly owing to their versatile, biocompatible, biodegradable, and non-toxic properties. Several types of chitosan-based drug delivery systems have been developed, including chemical modification, conjugates, capsules, and hybrids. They have been shown to be effective in improving intestinal assimilation of several types of drugs, e.g., antidiabetic, anticancer, antimicrobial, and anti-inflammatory drugs. In this review, the physiological challenges affecting intestinal drug absorption and the effects of chitosan on those parameters impacting on oral bioavailability are summarized. More appreciably, types of chitosan-based nanomaterials enhancing intestinal drug absorption and their mechanisms, as well as potential applications in diabetes, cancers, infections, and inflammation, are highlighted. The future perspective of chitosan applications is also discussed.